Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (treat angina with aggrastatρ [tirofiban] and determine cost of therapy with invasive or conservative strategy)-TIMI 18 trial

American Journal of Cardiology

Volumn 83, Issue 3, 1999, Pages 317-322

  Weintraub, William S ^a   Culler, Steven D ^b   Kosinski, Andrzej ^b   Becker, Edmund R ^b   Mahoney, Elizabeth ^a   Burnette, Joy ^a   Spertus, John A ^c   Feeny, David ^d   Cohen, David J ^e   Krumholz, Harlan ^f   Ellis, Stephen G ^g   Demopoulos, Laura ^h   Robertson, Deborah ^h   Boccuzzi, Stephen J ^h   Barr, Eliav ^h   Cannon, Christopher P ⁱ  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^d MCMASTER UNIVERSITY   (Canada)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h MERCK RESEARCH LABORATORIES   (United States)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TIROFIBAN;

ARTICLE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEART INFARCTION; HOSPITAL COST; HUMAN; MEDICAL FEE; OUTPATIENT CARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ANGINA PECTORIS; COST-BENEFIT ANALYSIS; DRUG COSTS; ECONOMICS, MEDICAL; FIBRINOLYTIC AGENTS; HOSPITAL COSTS; HUMANS; QUALITY OF LIFE; QUESTIONNAIRES; RELATIVE VALUE SCALES; TREATMENT OUTCOME; TYROSINE;

EID: 0033080936     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00860-1     Document Type: Article

References (30)

1. Weintraub W.S., Warner C.D., Mauldin P.D., Becker E.R., Gomes D., Cook J., Kosinski A., Boccuzzi S. Economic winners and losers after introduction of an effective new therapy depend on the type of payment system. Am J Managed Care. 3:1997;743-749.
2. Mark D.B., Cowper P.A., Berkowitz S.D., Davidson-Ray L., DeLong E.R., Turpie A.C.G., Califf R.M., Weatherley B., Cohen M. Economic assessment of low-molecular weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients results from the ESSENCE randomized trial . Circulation. 97:1998;1702-1707.
3. Midgette A.S., Wong J.B., Beshansky J.R., Porath A., Fleming C., Pauker S.G. Cost-effectiveness of streptokinase for acute myocardial infarction A combined meta-analysis and decision analysis of the effects of infarct location and of likelihood of infarction . Medical Decision Making. 14:1994;108-117.
4. Krumholz H.M., Pasternak R.C., Weinstein M.C., Friesinger G.C., Ridker P.M., Tosteson A.N.A., Goldman L. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med. 327:1992;7-13.
5. Mark D.B., Hlatky M.A., Califf R.M., Naylor C.D., Lee K.L., Armstrong P.W., Barbash G., White H., Simoons M.L., Nelson C.L., Clapp-Channing N., Knight J.D., Harrell F.E. Jr, Simes J., Topol E.J. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 332:1995;1418-1424.
6. Stone G.W., Grines C.L., Rothbaum D., Browne K.F., O'Keefe J., Overlie P.A., Donohue B.C., Chelliah N., Vlietstra R., Catlin T., O'Neill W.W. Analysis of the relative costs and effectiveness of primary angioplasty versus tissue-type plasminogen activator The Primary Angioplasty in Myocardial Infarction (PAMI) trial . J Am Coll Cardiol. 29:1997;901-907.
7. De Boer M.J., Van Hout B.A., Liem A.L., Suryapranata H., Hoorntje J.C.A., Zijlstra F. A cost-effective analysis of primary coronary angioplasty versus thrombolysis for acute myocardial infarction. Am J Cardiol. 76:1995;830-833.
8. Goldman L. Cost and quality of life thrombolysis and primary angioplasty . J Am Coll Cardiol. 25:(suppl):1995;38S-41S.
9. Goldman L., Sia S.T.B., Cook E.F., Rutherford J.D., Weinstein M.C. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonistsafter acute myocardial infarction. N Engl J Med. 319:1988;152-157.
10. Tsevat J., Duke D., Goldman L., Pfeffer M.A., Lamas G.A., Soukup J.R., Kuntz K.M., Lee T.H. Cost-effectiveness of captopril therapy after myocardial infarction. J Am Coll Cardiol. 26:1995;914-919.
11. Aumont M.-C., Seknadji P. Secondary prevention after myocardial infarction role of antiplatelet therapy and lipid lowering drugs . Arch Mal Coeur Vaiss. 8:1996;39-41.
12. Van Bergen P.F.M.M., Jonker J.J.C., Van Hout B.A., Van Domburg R.T., Deckers J.W., Azar A.J., Hofman A. Costs and effects of long-term oral anticoagulant treatment after myocardial infarction. JAMA. 273:1995;925-928.
13. Johannesson M., Jonsson B., Kjekshus J., Olsson A.G., Pedersen T.R., Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med. 336:1994;332-336.
14. Oldridge N., Furlong W., Feeny D., Torrance G., Guyatt G., Crowe J., Jones N. Economic evaluation of cardiac rehabilitation soon after acute myocardial infarction. Am J Cardiol. 72:1993;154-161.
15. Krumholz H.M., Cohen B.J., Tsevat J., Pasternak R.C., Weinstein M.C. Cost-effectiveness of a smoking cessation program after myocardial infarction. J Am Coll Cardiol. 22:1993;697-702.
16. Conti C.R. Unstable angina cost of conservative and invasive strategies using TIMI 3B as a model . Clin Cardiol. 18:1995;187-188.
17. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation. 96:1997;1445-1453.
18. RESTORE Economic Study Group. Analysis of hospital costs and outcomes in RESTORE (abstr). J Am Coll Cardiol 1997;29:395A.
19. Mark D.B., Talley J.D., Topol E.J., Bowman L., Lam L.C., Anderson K.M., Jollis J.G., Cleman M.W., Lee K.L., Aversano T., Untereker W.J., Davidson-Ray L., Califf R.M. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. Circulation. 94:1996;629-635.
20. Cella D. Functional status and quality of life: current views on measurement and intervention. In: Functional Status and Quality of Life in Persons with Cancer. American Cancer Society, Atlanta, GA, 1992.
21. Conn V.S., Taylor S.G., Wiman P. Anxiety, depression, quality of life, and self-care among survivors of myocardial infarction. Issues in Mental Health Nurs. 12:1991;321-331.
22. Frasure-Smith N., Lesparance F., Falajic M. Depression following myocardial infarction. JAMA. 270:1993;1819-1825.
23. Hirsch W., Ledley G.S., Calderon D., Dowds A., Yazdanfar S., Kotler M.N. The effect of age on quality of life changes after angioplasty (abstr). Chest. 108:1995;112S.
24. Spertus JA, McDonell M, Fihn SD. Depression is associated with worse disease-specific functional status among patients with coronary artery disease (abstr). Circulation 1997;96 (suppl I):I-398.
25. Weintraub W.S., Mauldin P.D., Becker E.R., Kosinski A.S., King S.B. III. A comparison of the costs and quality of life after coronary angioplasty or coronary surgery for multivessel coronary artery disease results from the Emory Angioplasty versus Surgery Trial (EAST) . Circulation. 92:1995;2831-2840.
26. Lee J.S., Bailey M.J., Jeong J., Mauldin P.D., Weintraub W.S. A study on the cost-effectiveness of coronary revascularization introducing the simultaneous mimic health status model . Health Econ. 6:1997;613-623.
27. Hsiao W.C., Braun P., Yntema D., Becker E.R. Estimating physicians' work for a resource-based relative-value scale. N Engl J Med. 319:1988;835-841.
28. Becker ER, Mauldin PD, Bernadino ME. Using physician work RVUs to profile surgical packages: methods and results for kidney transplant surgery. Best Prac Benchmarking Healthc 1996:1-7.
29. Feeny D.H., Torrance G.W., Furlong W.J. Health utilities index. Spilker B. Quality of Life and Pharmacoeconomics in Clinical Trials. 1996;239-252 Lippincott-Raven Press, Philadelphia.
30. Spertus J.A., Winder J.A., Dewhurst T.A., Deyo R.A., Fihn S.D. Monitoring the quality of life in patients with coronary artery disease. Am J Cardiol. 74:1994;1240-1244.